 "Suven Life Sciences surges on securing patents for neurodegenerative drug")
Suven Life Sciences has surged 6% to Rs 220 on BSE after the pharmaceuticals company said it has been granted product patents by Australia, Hong Kong and Japan, for drug used in the treatment of neurodegenerative diseases.
“The company has secured one product patent from Australia, two product patents from Japan and one product patent from Hong Kong corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2030,” Suven Life Sciences said in a BSE filing.
With these new patents, Suven has a total of 19 granted patents from Australia, 14 granted patents from Japan and 15 granted patents from Hong Kong, it added.
The stock opened at Rs 211 and hit a high of Rs 226 on BSE. Till 1042 hours, a combined 1.43 million shares changed hands against an average sub one million shares that were traded daily in past two weeks on BSE and NSE.
“The company has secured one product patent from Australia, two product patents from Japan and one product patent from Hong Kong corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2030,” Suven Life Sciences said in a BSE filing.
With these new patents, Suven has a total of 19 granted patents from Australia, 14 granted patents from Japan and 15 granted patents from Hong Kong, it added.
The stock opened at Rs 211 and hit a high of Rs 226 on BSE. Till 1042 hours, a combined 1.43 million shares changed hands against an average sub one million shares that were traded daily in past two weeks on BSE and NSE.